In vivo cell therapy

Basecamp raises $140M to push model-designed recombinases toward in vivo cell therapy

The company says the money will train the next generation of its EDEN models. The published evidence so far is one January bioRxiv preprint, co-authored with Nvidia, whose venture arm also put money into the round.